Why is Hester Bios falling/rising?

As of 05-Sep, Hester Biosciences Ltd is experiencing a price increase, currently at 2,125.45, reflecting a rise of 32.45 or 1.55%. The stock has shown strong performance recently, outperforming its sector by 1.62% today and achieving a consecutive gain over the last two days with a total return of 3.76%. It has also reached an intraday high of Rs 2,170.6, indicating positive momentum. The company has reported very positive financial results, including a 145.1% growth in net profit and consistent positive results over the last five quarters. However, concerns remain regarding its high Debt to EBITDA ratio of 3.49 times, which indicates a low ability to service debt, and its relatively poor long-term growth metrics, with net sales and operating profit growing at only 11.90% and 5.48% annually over the last five years, respectively.
In the broader market context, Hester Bios has outperformed the Sensex in the short term, with a 1-week return of 4.70% compared to the Sensex's 1.13%. Despite this positive short-term performance, the stock has struggled year-to-date, showing a decline of 11.17% while the Sensex has increased by 3.29%. The stock's valuation appears expensive with a PEG ratio of 0.5, suggesting that while it is trading at a discount compared to peers, the market may still be cautious given the company's low return on capital employed and minimal domestic mutual fund investment. This mixed performance indicates that while recent gains are encouraging, underlying financial challenges may temper long-term investor confidence.